FDA warned OrganiCare its 'kills 99.9% of herpes' ointments are unapproved drugs

On 1 October 2026 the FDA's Center for Drug Evaluation and Research wrote to OrganiCare's Caroline Goodner: the company's 'HClear for him' and 'FemiClear Genital Herpes Symptoms' ointments, sold through femiclear.com and promoted on its Facebook and Instagram accounts, are unapproved new drugs under section 505(a) of the FD&C Act — illegal to introduce into interstate commerce.

The labeling reviewed in July 2026 promised fast-acting genital herpes symptom relief, said '>90% OF USERS REPORTED LESS SEVERE OUTBREAKS', that the ointment 'kills 99.9% of the herpes simplex I & II viruses', and that over 50% of users experienced no blisters when used at the first sign. FDA's letter stressed it has approved no over-the-counter drug for the treatment, cure, mitigation or prevention of any STI, and that relying on such products can mean forgoing care, risking infertility, sepsis and unknowingly transmitting infections.

It was not OrganiCare's first claims problem: in 2020 the National Advertising Division found the company's evidence didn't support claims that FemiClear out-killed Monistat on yeast. The 2026 letter escalated the same pattern — claims outrunning proof — from an advertising-accuracy slap to a drug-regulation violation.

No fine stated, but the two flagship products stand as unapproved drugs, with seizure and injunction threatened if the violations continue

The violation is categorical, not about evidence quality: no OTC STI product of any kind has FDA approval

The claims were quantified and specific — 99.9% virus kill rates, 90%-plus user outcomes — the kind of numbers that invite regulator math

It shows a repeat pattern across six years and two regulators, from NAD advertising review to an FDA drug warning

A marketing-claims regulator saying 'unproven' is a warning; a drug regulator saying 'unapproved' is a different game — efficacy stats don't cure a missing approval.

FDA gave OrganiCare the standard warning-letter window to correct the violations promptly, warning that failure could bring regulatory or legal action — including seizure and injunction — without further notice; the letter went to the CEO directly.